Pembrolizumab – November 2021

• Brand names:
  • Keytruda®
• Pharmaceutical Company:
  • Merck Sharp & Dohme (Australia) Pty Ltd
• Condition/Indication: Oesophageal carcinoma or HER-2-negative gastroesophageal adenocarcinoma
• Meeting Date: November 2021
• Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1311KB)
• Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 320KB)

Related Public Summary Documents

Pembrolizumab – March 2022